IONS supply chain intelligence for Ionis Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| SWEDISH-ORPHAN-BIOVITRUM-AB | SWEDISH-ORPHAN-BIOVITRUM-AB | 92% | Under our agreements, we are responsible for supplying finished goods inventory to Sobi and Sobi is responsible for selling each medicine to the end customer. |
| MGX | Metagenomi Therapeutics, Inc. | 85% | Reciprocal relationship from MGX graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: elopment, manufacture and commercialization of programs or product candidates.… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | ible to receive tiered royalties up to 30 percent on net sales. From inception through December 31, 2025, we have generated more than $125 million in payments under these collaborations. 16 PTC Thera… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: ible to receive tiered royalties up… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we u… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IONS graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from IONS graph: Reciprocal relationship from ARWR g… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: Reciprocal relationship from IONS graph: Reciprocal relationship from DYN graph: Reciprocal relationship from IONS graph: Reciprocal relationship from DYN grap… |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: Reciprocal relationship from IONS graph: Reciprocal relationship from PTCT graph: rmaceutical products for which marketing authorization has been granted are … |
| TMO | Thermo Fisher Scientific Inc. | 72% | Reciprocal relationship from TMO graph: Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service providers to conduct our clinical studies f… |
| TMO | Thermo Fisher Scientific Inc. | 72% | vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we u… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AZN | AstraZeneca PLC | 92% | Reciprocal relationship from AZN graph: Reciprocal relationship from IONS graph: We determined that we had a vendor-customer relationship within the scope of ASC Topic 606, Revenue from Contracts wit… |
| AZN | AstraZeneca PLC | 92% | We determined that we had a vendor-customer relationship within the scope of ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, for the license we granted to AstraZeneca |
| ROCHE | ROCHE | 90% | We earned the following revenue from our relationship with Roche |
| ICON-CLINICAL-RESEARCH-LIMITED-MEDPACE-INC-PAREX | ICON-CLINICAL-RESEARCH-LIMITED-MEDPACE-INC-PAREX | 85% | inical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For exam… |
| SYNEOS-HEALTH-INC | SYNEOS-HEALTH-INC | 85% | inical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For exam… |
| TMO | Thermo Fisher Scientific Inc. | 85% | vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we u… |
| TMO | Thermo Fisher Scientific Inc. | 85% | Reciprocal relationship from TMO graph: Reciprocal relationship from IONS graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IONS graph: vestigators, contract research organi… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ALNY graph: Reciprocal relationship from IONS graph: nt of certain development, regulatory and sales events. We will also reimburse Metagenomi for certain of its costs in… |
| ALNY | Alnylam Pharmaceuticals, Inc. | 72% | nt of certain development, regulatory and sales events. We will also reimburse Metagenomi for certain of its costs in conducting its research and drug discovery activities under the collaboration. Ot… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | h arrangements with collaborative partners or others, which could require us to give up rights to certain of our technologies or medicines. We have incurred losses, and our business will suffer if we… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ARWR graph: Reciprocal relationship from IONS graph: h arrangements with collaborative partners or others, which could require us to give up rights to certain of our tech… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MGX graph: elopment, manufacture and commercialization of programs or product candidates.… |
| MTVA | MetaVia Inc. | 72% | Reciprocal relationship from MTVA graph: Reciprocal relationship from IONS graph: Reciprocal relationship from MTVA graph: ing. Accordingly, shares registered under such registration statements will … |
| PTCT | PTC Therapeutics, Inc. | 72% | Reciprocal relationship from PTCT graph: rmaceutical products for which marketing authorization has been granted are subject to extensive and rigorous regulation; ● Failure to obtain and maintain acc… |
| AKCEA-THERAPEUTICS-INC | AKCEA-THERAPEUTICS-INC | 62% | cussed in this report on Form 10-K, including those identified in Item 1A, Risk Factors . Although our forward-looking statements reflect the good faith judgment of our management, these statements a… |
| ISIS-PHARMACEUTICALS-INC | ISIS-PHARMACEUTICALS-INC | 62% | cussed in this report on Form 10-K, including those identified in Item 1A, Risk Factors . Although our forward-looking statements reflect the good faith judgment of our management, these statements a… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| IONS-DEBT-10330 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-12-31. |
| IONS-DEBT | Debt stack $2.6B | 90% | Market cache reports total debt of $2.6B. |
| IONS-DEBT-10329 | Warrants outstanding: 4250000 | 90% | xbrl warrant detail from xbrl 2021-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| IONS-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 496 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 2 | |
| BTAI | BioXcel Therapeutics, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer'] |
| DEO | Diageo plc | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 1 | ['spend'] |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | ['supplier'] |
| CAPR | Capricor Therapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 2 |